ImmunityBio, Inc. (IBRX) vs Madrigal Pharmaceuticals, Inc. (MDGL)
A side-by-side comparison of ImmunityBio, Inc. and Madrigal Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
IBRX
ImmunityBio, Inc.
$9.69HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
MDGL
Madrigal Pharmaceuticals, Inc.
$495.65HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — IBRX vs MDGL
growth of $100 · dividends reinvested · last 10yIBRX +38.8% (+3.3%/yr)MDGL +2930.2% (+40.7%/yr)MDGL compounded faster over this window
Log scale — wide-divergence pair
IBRX MDGL
IBRX vs MDGL: by the numbers
- •MDGL is the larger company ($11.45B vs $10.15B market cap).
- •Both run net losses; MDGL's is the smaller (-25.32% vs -598.56% net margin).
Metrics side by side
Valuation
| Metric | IBRX | MDGL |
|---|---|---|
| P/S ratio | 61.21 | 8.92 |
| P/B ratio | N/A | 21.87 |
Profitability
| Metric | IBRX | MDGL |
|---|---|---|
| Gross margin | 94.63% | 91.48% |
| Operating margin | -226.00% | -25.13% |
| Net margin | -598.56% | -25.32% |
| ROE | N/A | -62.07% |
| ROIC | -45.63% | -37.02% |
Growth (annualized)
| Metric | IBRX | MDGL |
|---|---|---|
| Revenue CAGR (5Y) | 202.97% | N/A |
| Total return CAGR (5Y) | 0.39% | 44.41% |
Frequently asked
- How have IBRX and MDGL total returns compared?
- Over the past 10 years, IBRX delivered 2.95% and MDGL delivered 41.50% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
ImmunityBio ROEMadrigal Pharmaceuticals ROEImmunityBio operating marginMadrigal Pharmaceuticals operating marginImmunityBio revenue growthMadrigal Pharmaceuticals revenue growthImmunityBio free cash flowMadrigal Pharmaceuticals free cash flow
ImmunityBio & Madrigal Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.